Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary GSK will discontinue camlipixant, the chronic cough treatment it gained through its acquisition of Bellus Health. Two pivotal trials produced conflicting results. One dose worked in one study and
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Zymeworks agreed to acquire Theravance Biopharma for $929 million, following the failure of ampreloxetine in neurogenic orthostatic hypotension. Consequently, Theravance entered a strategic review that identified its approved portfolio
Summary Ipsen announced the acquisition of Swiss biotech Memo Therapeutics on July 1, 2026. The deal is valued at up to $800 million, with €200 million upfront and more than
Why CVRs Are Becoming the Quiet Engine Behind Today’s Biotech Deals The biotech sector is navigating one of the most complex market environments in recent memory. Volatile valuations, cautious capital,
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
Use this checklist to rapid-fire your due diligence – ensure each asset in your portfolio meets critical payer evidence expectations across all ten domains. The 10 Critical P&R Due Diligence